Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting
Data from Pivotal Trial to be Highlighted in Oral Presentation on Saturday, March 19 Investor Event to be Held Sunday, March 20 at 7:30 am MST WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 10, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 28, 2022 , the compensation committee of the Company’s Board of Directors approved grants
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and 2021 Financial Results
Positive Top-Line Data from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer; Detailed Results to be Presented in Plenary Session at SGO in March Mirvetuximab BLA On Track for Submission this Quarter IMGN632 Triplet Data Demonstrating Manageable Safety Profile and Encouraging
View HTML
Toggle Summary ImmunoGen Announces Webcast of Panel Discussion at Upcoming Cowen 42nd Annual Health Care Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will participate in the ovarian cancer panel discussion at the
View HTML
Toggle Summary ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform ImmunoGen to Receive a $13 Million Upfront Payment for Initial Targets; Eligible to Receive an Additional $32.5
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 10, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming SVB Leerink 11th Annual Global Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 4, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, and Anna Berkenblit , Chief Medical Officer, will
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 31, 2022 , the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 31, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga , MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 3, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2021 the compensation committee of the Company’s Board of Directors granted a
View HTML